{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:00Z","timestamp":1787020260353,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2023040"],"award-info":[{"award-number":["PX2023040"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82103497"],"award-info":[{"award-number":["No. 82103497"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13997-1","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:55:16Z","timestamp":1744613716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune checkpoint inhibitor-related myocarditis in patients with lung cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Wenli","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieran","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"12","key":"13997_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, et al. Effect of First-Line Serplulimab vs placebo added to chemotherapy on survival in patients with Extensive-Stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332.","journal-title":"JAMA"},{"issue":"11","key":"13997_CR2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous Non-Small-Cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"11","key":"13997_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, Rodr\u00edguez-Cid J, Tafreshi A, Cheng Y, Lee KH, et al. Pembrolizumab plus chemotherapy in squamous Non-Small-Cell lung cancer: 5-Year update of the phase III KEYNOTE-407 study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10","key":"13997_CR4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J Clin Invest. 2007;117(10):2974\u201382.","journal-title":"J Clin Invest"},{"issue":"8","key":"13997_CR5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","volume":"206","author":"KS Peggs","year":"2009","unstructured":"Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717\u201325.","journal-title":"J Exp Med"},{"issue":"12","key":"13997_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852\u201363.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"13997_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"13997_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"2","key":"13997_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1042\/CS20181003","volume":"133","author":"J Inthagard","year":"2019","unstructured":"Inthagard J, Edwards J, Roseweir AK. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clin Sci (Lond). 2019;133(2):181\u201393.","journal-title":"Clin Sci (Lond)"},{"key":"13997_CR10","doi-asserted-by":"crossref","unstructured":"Frigeri M, Meyer P, Banfi C, Giraud R, Hachulla AL, Spoerl D, Friedlaender A, Pugliesi-Rinaldi A, Dietrich PY. Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. Can J Cardiol 2018;34(1):92.e91-92.e93.","DOI":"10.1016\/j.cjca.2017.09.025"},{"issue":"10124","key":"13997_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.","journal-title":"Lancet"},{"issue":"12","key":"13997_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"16","key":"13997_CR13","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"41","key":"13997_CR14","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"2","key":"13997_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-Oncology. Circulation. 2019;140(2):80\u201391.","journal-title":"Circulation"},{"issue":"3","key":"13997_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, et al. NCCN guidelines insights: management of Immunotherapy-Related toxicities, version 1.2020. J Natl Compr Cancer Network: JNCCN. 2020;18(3):230\u201341.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"1","key":"13997_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"13997_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaccao.2020.07.005","volume":"2","author":"MYY Moey","year":"2020","unstructured":"Moey MYY, Tomdio AN, McCallen JD, Vaughan LM, O\u2019Brien K, Naqash AR, Cherry C, Walker PR, Carabello BA. Characterization of immune checkpoint Inhibitor-Related cardiotoxicity in lung cancer patients from a rural setting. JACC CardioOncol. 2020;2(3):491\u2013502.","journal-title":"JACC CardioOncol"},{"issue":"10","key":"13997_CR19","doi-asserted-by":"publisher","first-page":"e7233","DOI":"10.1002\/cam4.7233","volume":"13","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Chen Z, Song W, Xu Y, Zhao Z, Sun Y, Wang Y, Geng X, Zhao J, Zhang X, et al. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study. Cancer Med. 2024;13(10):e7233.","journal-title":"Cancer Med"},{"issue":"6","key":"13997_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, Stein F, Bretagne M, Ederhy S, Fenioux C, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473\u201386.","journal-title":"Circulation"},{"key":"13997_CR21","doi-asserted-by":"publisher","first-page":"1158690","DOI":"10.3389\/fonc.2023.1158690","volume":"13","author":"C Jin","year":"2023","unstructured":"Jin C, Qi J, Wang Q, Pu C, Tan M. Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. Front Oncol. 2023;13:1158690.","journal-title":"Front Oncol"},{"issue":"7","key":"13997_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","volume":"32","author":"D Rodr\u00edguez-Abreu","year":"2021","unstructured":"Rodr\u00edguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, D\u00f3mine M, Cheng SY, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881\u201395.","journal-title":"Ann Oncol"},{"issue":"11","key":"13997_CR23","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","volume":"23","author":"Y Toi","year":"2018","unstructured":"Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, et al. Association of Immune-Related adverse events with clinical benefit in patients with advanced Non-Small-Cell lung cancer treated with nivolumab. Oncologist. 2018;23(11):1358\u201365.","journal-title":"Oncologist"},{"issue":"3","key":"13997_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint Blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583\u20139.","journal-title":"Ann Oncol"},{"issue":"11","key":"13997_CR25","doi-asserted-by":"publisher","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","volume":"5","author":"O Hasan Ali","year":"2016","unstructured":"Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Fr\u00fch M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology. 2016;5(11):e1231292.","journal-title":"Oncoimmunology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13997-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:55:17Z","timestamp":1744613717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13997-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13997"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13997-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Peking University Cancer Hospital (IRB number: 2023KT40). Each patient signed an informed consent form before treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"685"}}